Xeris Biopharma Holdings Inc. (XERS), headquartered in Chicago, Illinois, is a prominent name in the field of pharmaceuticals, specializing in the development and commercialization of innovative, ready-to-use, and patient-friendly injectable and infusible drug formulations. The company’s proprietary XeriSol™ and XeriJect™ formulation technologies allow for the creation of ready-to-use liquid formulations of drugs that conventionally require reconstitution, refrigeration, constant agitation, or dilution.
Xeris Biopharma is well renowned for its novel approach to treating hypoglycemia, a critical condition often encountered in people living with diabetes. The company has shown its prowess in the industry by being the first to commercialize a ready-to-use, room-temperature stable glucagon, Gvoke®, for the emergency treatment of severe hypoglycemia. Gvoke® is available in both prefilled syringe (PFS) and autoinjector formats, providing fast and reliable treatment options for patients and caregivers in need.
Furthermore, XER-S3, Xeris’s developmental drug for the treatment of congenital hyperinsulinism, is in its Phases 2 and 3 and will further solidify its position as a market leader, providing pioneering solutions for those affected with this rare condition. Xeris’s commitment to deliver innovative and convenient drugs extends to other areas too, with diverse products under development in several therapeutic areas including epilepsy, adrenal insufficiency, and hypoglycemia.
Xeris Biopharma Holdings, Inc. operates on principles of developing breakthrough products which are patient-centric and bring convenience and effectiveness together. With a cutting-edge proprietary technology and an unyielding dedication to innovation, Xeris continues to strive for improving the lives of people with serious, chronic conditions and acute care needs.
The stock market recognizes Xeris Biopharma under the ticker symbol “XERS” on the NASDAQ Exchange. With a steady focus on its various research and development initiatives, Xeris has been able to secure its position in the competitive pharmaceuticals market, and continues on its dedicated path towards bringing effective, easy-to-use medication closer to those who need it. With robust growth strategies and continuous advancements in its proprietary technologies, Xeris Biopharma holds an optimistic future in the industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Xeris Biopharma Holdings reported a record-breaking Q2 2026 with $92 million in total revenue, driven by 34% year-over-year growth in net product revenue, primarily from Recorlev's 81% growth. The company strengthened its IP, retired convertible notes saving $3 million in annual interest, and raised its full-year 2026 revenue guidance to $385-$390 million. Significant progress was also made on the XP8121 pipeline with a Phase 3 start expected by year-end, positioning the company for continued growth.
Danish pharmaceutical company H Lundbeck is reportedly exploring a potential takeover of Chicago-based Xeris Pharmaceuticals Inc, a commercial-stage drugmaker. While discussions are preliminary and Xeris stated it is "not for sale," Lundbeck is working with financial advisers to consider the acquisition. The move would expand Lundbeck's presence into rare endocrine disorders, leveraging Xeris's $1.8 billion market valuation against Lundbeck's larger $6.6 billion market cap.
Danish drugmaker H Lundbeck A/S is reportedly considering an acquisition of Chicago-based Xeris Biopharma, known for its injectable treatments for endocrine and rare conditions. Lundbeck has engaged advisers to assess a potential deal, though Xeris has stated it is not for sale. The news sent Xeris shares to a 2019 high, while Lundbeck's stock dipped slightly.
Danish drugmaker Lundbeck has reportedly shown interest in acquiring Xeris Biopharma, causing a 15% surge in XERS shares, despite Xeris stating it is "not for sale." Xeris boasts a promising pipeline, including XP-8121 with projected peak annual revenues between $1 billion and $3 billion, and reported a 29% year-over-year increase in Q2 revenue, driven by strong Recorlev sales. The company maintains a solid financial foundation with $121.7 million in cash, supporting future R&D and market expansion.
Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, sold 25,000 shares on September 28, 2026. This transaction is valued at $250,000. Further details are available to premium subscribers.